We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Inion Oy | IIN | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.36 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.36 | 0.36 |
| Top Posts |
|---|
Posted at 11/8/2008 08:22 by pre Out-licensing agreement (Inion Oy)RNS Number : 0340B Inion Oy 11 August 2008 Inion Oy ("Inion or the "Company") Inion licenses bioactive bone regrowth technology to US company Curative Biosciences Inc. Tampere, Finland and Guildford, UK. 11 August 2008, Inion (LSE: IIN.L), today announces the signature of an out-licensing agreement with US company, Curative Biosciences Inc. (Waltham, MA), covering certain of its novel bioactive technologies for the promotion of bone regrowth and repair when treating patients undergoing orthopaedic surgical procedures. Under the terms of the licensing agreement, Curative Bioscience Inc. will pay to Inion a small upfront fee, development and sales milestones of up to US$2,025,000 and royalties on revenues generated from any products developed using the technology. The licensed technology is based on the use of N,N-dimethylacetamid pharmaceutically acceptable salts and prodrugs, either alone or incorporated in resorbable polymer structures (such as plates, membranes and screws) for implantation in patients. Patent applications covering this technology in the UK and internationally have been filed and are pending. Chris Lee, Inion's CEO, said: "DMA was discovered to have bioactive properties in promoting bone repair and regrowth through research work undertaken at our Cambridge facility prior to its closing last year. Inion, however, is no longer pursuing early stage development work in this area as it focuses on the commercialisation of its existing product portfolio for spinal surgery and orthopaedic trauma. By out-licensing non-core intellectual property and technologies, such as DMA, we seek to realise the value resulting from our research through companies more focused in these areas." -ends- For further information, please contact: Inion Oy Tel: +44 (0)1483 685390 Chris Lee, Chief Executive Officer Julien Cotta, Chief Financial Officer Citigate Dewe Rogerson Tel: +44 (0)207 638 9571 Mark Swallow / David Dible About Inion (www.inion.com) Inion Oy is a medical devices company focused on the development and successful commercialisation of innovative and unique biodegradable and bioactive surgical implants in selected high value orthopaedic market segments. Inion's core expertise and technology lies in the design and manufacture of innovative biodegradable plates, screws, pins and membranes, which are used to enhance the healing of bone or soft tissue injuries to the skeleton, such as those caused by trauma or by reconstructive surgery. Inion implants are made from its proprietary Inion Optima* family of biomaterials, with properties tailored for specific surgical applications, in terms of strength, flexibility and rate of degradation Inion is also focused on developing proprietary new bioactive and biodegradable biomaterials that promote bone healing and accelerate patient rehabilitation. Inion was incorporated in early 2000 and listed on the Official List of the UK Listing Authority in December 2004 (ticker: IIN). The Company has offices in the UK and USA, and its head office, R&D and production facilities are in Tampere, Finland. This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group's products), and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to Inion's funding requirements, regulatory approvals, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statement. This information is provided by RNS The company news service from the London Stock Exchange END |
Posted at 06/8/2008 08:59 by mikey34 PRE,Agreed.The mkt has battered co's with small mkt caps and profits not in the bag now.But this co has excellent prospects long term for the patient investor IMO. |
Posted at 15/7/2008 08:06 by pre Cracking RNS....regulatory approval obtained:-)))))))Regulatory Approval (Inion Oy) RNS Number : 0510Z Inion Oy 15 July 2008 Inion Oy ("Inion or the "Company") Inion receives 510(k) marketing clearance to sell its biodegradable graft containment systems in the USA for spinal fusion procedures Tampere, Finland and Guildford, UK. 15 July 2008, Inion (LSE: IIN.L), the company focused on the development and commercialisation of novel biodegradable medical implants, today announces it has received 510(k) marketing clearance from the US Food and Drug Administration (FDA) for its biodegradable graft containment systems for spinal fusion procedures. The US marketing clearance has been received for the Inion S-1* Anterior Cervical Fusion System, the Inion S-1* double-level plate and the Inion S-2* Anterior Thoraco-Lumbar Fusion System. These systems consist of biodegradable plates and screws, which are designed for bone graft containment in spinal fusion procedures. Such procedures are carried out as a treatment for a range of spinal conditions including ruptures and displacement of inter-vertebral discs. Inion's S-1* and Inion S-2* graft containment systems include implants intended for use along the entire length of the spine in conjunction with traditional rigid fixation. These new graft containment systems also incorporate a radiographic marker to the edges of the plates and to the tips of screws. These markers enable surgeons to view the position of the implants in post-operative x-ray without interfering with their assessment of the site of surgery and its healing progress. More than 183,000 cervical plating procedures (Ref. 1) and more than 10,000 anterior thoraco-lumbar plating procedures (Ref. 2) were performed in 2006 in the USA. The US market for these procedures was worth approximately EUR318 million and EUR32 million, respectively. The number of spinal plating procedures has since grown at an annual rate of approximately 30%. Inion's biodegradable implants offer significant clinical benefits over traditional metal materials, primarily in that they slowly and completely degrade over time into carbon dioxide and water, which are absorbed into the body. The Inion S-1* and Inion S-2* graft containment systems received CE Mark marketing clearance in Europe in August 2007 and September 2007, respectively. Chris Lee, Inion's CEO, said: "The US marketing clearance for our biodegradable spine products is great news. We are already seeing increased uptake of this important product line in Europe where awareness and acceptance of the clinical benefits of biodegradable medical implants is rapidly growing among surgeons, who are adopting this technology into their practice. Our aim now is to push these new biodegradable products aggressively into the US spine market where we believe it will make an attractive alternative to traditional metal plates and a strong driver of value for the Company." References 1. Spinemarket, Inc: US spinal implant market: Cervical plate analysis. 2007 2. Spinemarket, Inc: US spinal implant market: Anterior lumbar plating analysis. 2007 -ends- For further information, please contact: Inion Oy Tel: +44 (0)1483 685390 Chris Lee, Chief Executive Officer Julien Cotta, Chief Financial Officer Citigate Dewe Rogerson Tel: +44 (0)207 638 9571 Mark Swallow / David Dible About Inion (www.inion.com) Inion Oy is a medical devices company focused on the development and successful commercialisation of innovative and unique biodegradable and bioactive surgical implants in selected high value orthopaedic market segments. Inion's core expertise and technology lies in the design and manufacture of innovative biodegradable plates, screws, pins and membranes, which are used to enhance the healing of bone or soft tissue injuries to the skeleton, such as those caused by trauma or by reconstructive surgery. Inion implants are made from its proprietary Inion Optima* family of biomaterials, with properties tailored for specific surgical applications, in terms of strength, flexibility and rate of degradation Inion is also focused on developing proprietary new bioactive and biodegradable biomaterials that promote bone healing and accelerate patient rehabilitation. Inion was incorporated in early 2000 and listed on the Official List of the UK Listing Authority in December 2004 (ticker: IIN). The Company has offices in the UK and USA, and its head office, R&D and production facilities are in Tampere, Finland. This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group's products), and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to Inion's funding requirements, regulatory approvals, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statement. This information is provided by RNS The company news service from the London Stock Exchange END REAZGGMNGDLGRZZ |
Posted at 04/7/2008 08:24 by pre Pre-close Trading Update (Inion Oy)RNS Number : 3088Y Inion Oy 04 July 2008 Inion Oy ("Inion or the "Company") Pre-close Trading Update Tampere, Finland and Guildford, UK. 4 July 2008, Inion (LSE: IIN.L), the company focused on the development and commercialisation of novel biodegradable medical implants, today provides an update on 2008 trading, ahead of its half-yearly results announcement expected in August 2008. Based on the unaudited figures for the six months to 30 June 2008, the Directors anticipate that revenues for the period will be approximately EUR2.6 million, up 12% on the corresponding period in 2007. Invoiced sales of EUR1.8 million for the second quarter were 115% higher than in the first quarter of 2008, and 34% higher than in the corresponding period in 2007. These positive trends lead us to believe that Inion is on track to meet current market expectations of circa EUR7.0 million in sales for the full year 2008. Significantly, within these growth figures there is evidence to suggest Inion is starting to gain traction in the important US market. Chris Lee, Inion's CEO, said: "We continue to make good progress with executing our commercial strategy and are pleased to see sales growing strongly across our focused market segments. This uplift in sales is as a result of our commercial teams in these areas becoming more effective and an increasing awareness and acceptance among surgeons of the clinical benefits our biodegradable products can bring." -ends- For further information, please contact: Inion Oy Tel: +44 (0)1483 685390 Chris Lee, Chief Executive Officer Julien Cotta, Chief Financial Officer Citigate Dewe Rogerson Tel: +44 (0)207 638 9571 Mark Swallow / David Dible About Inion (www.inion.com) Inion Oy is a medical devices company focused on the development and successful commercialisation of innovative and unique biodegradable and bioactive surgical implants in selected high value orthopaedic market segments. Inion's core expertise and technology lies in the design and manufacture of innovative biodegradable plates, screws, pins and membranes, which are used to enhance the healing of bone or soft tissue injuries to the skeleton, such as those caused by trauma or by reconstructive surgery. Inion implants are made from its proprietary Inion Optima* family of biomaterials, with properties tailored for specific surgical applications, in terms of strength, flexibility and rate of degradation Inion is also focused on developing proprietary new bioactive and biodegradable biomaterials that promote bone healing and accelerate patient rehabilitation. Inion was incorporated in early 2000 and listed on the Official List of the UK Listing Authority in December 2004 (ticker: IIN). The Company has offices in the UK and USA, and its head office, R&D and production facilities are in Tampere, Finland. This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group's products), and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to Inion's funding requirements, regulatory approvals, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statement. This information is provided by RNS The company news service from the London Stock Exchange END TSTFKNKDOBKDQOK |
Posted at 19/1/2007 10:28 by mattyfromtheblock This is a step in the right direction-------------------- Inion Oy 19 January 2007 Inion Expands Biodegradable Medical Implant Product Ranges in Europe Inion ANCHRONTM Plus Suture Anchor System receives CE Mark Tampere, Finland and Takeley, UK. 19 January 2007...Inion (LSE: IIN.L), a company focused on the development of novel biodegradable medical implants, has received CE Mark from the British Standards Institution (BSI) for the Inion ANCHRONTM Plus Suture Anchor device for both orthopaedic and sports medicine applications. This product received equivalent 510(k) regulatory clearance for marketing in the USA in November 2006. CE Mark is required by a number of accredited bodies to medical device manufacturers prior to commercial distribution in the European Union. Inion ANCHRONTM Plus with CP-FiberTM suture is an innovative biodegradable medical system for use in soft tissue to bone fixation (e.g. for repair of ligament/tendon rupture or detachment) and can be used for repairing a range of injuries. It has particular application in the shoulder, such as for rotator cuff and instability repairs (such as Bankart and SLAP lesions). The system can also be used to repair injuries in the elbow, ankle and knee. The high grade CP-FiberTM suture offers special advantages over traditional polyester sutures, including superior handling properties and increased strength. Inion ANCHRONTM Plus supersedes Inion ANCHRONTM, Inion's first biodegradable anchor system, and is a new addition to Inion's range of sports medicine devices made from the Company's proprietary Inion OPTIMATM range of biomaterials. This range includes Inion HEXALONTM, the world's first coloured biodegradable repair device for the cruciate ligaments in the knee; Inion TRINIONTM, the biodegradable meniscal screw for the repair of torn knee cartilage; and Inion ANCHRONTM, which received its CE Mark and 510(k) approval in 2005. Dr Auvo Kaikkonen, CEO of Inion commented, 'We are very pleased to have received a CE Mark for Inion ANCHRONTM Plus, allowing patients and surgeons across Europe access to a product that we believe offers a considerable performance advantage over other suture anchors currently available.' CP-FiberTM is a trademark of CP Medical, Inc., Portland, OR, USA. -Ends- Inion Oy Dr Auvo Kaikkonen, Chief Executive Officer Tel: +44 1279 874 222 Dr Kirk Andriano, VP of R&D Tel: +44 1223 394 206 Citigate Dewe Rogerson Tel: +44 207 638 9571 Mark Swallow / David Dible / Helena Galilee About Inion (www.inion.com) Inion Oy is a Finnish company that specializes in the development of biodegradable medical implants. The Inion core expertise and technology lies in the design and manufacture of innovative biodegradable plates, screws, pins and membranes that are used to enhance the healing of skeletal injuries (bone and soft tissue), such as those caused by trauma or by reconstructive surgery. Inion implants are made from its proprietary Inion OptimaTM family of biomaterials, with properties tailored for specific surgical applications, in terms of strength, flexibility and rate of degradation. Inion has developed and launched products in five strategic business areas - cranio-maxillofacial surgery, orthopaedic trauma, sports medicine, dental surgery and most recently in the spinal implant area - in nearly 50 countries worldwide. Inion was incorporated in early 2000 by an international team of experts in biodegradable materials and their clinical applications, and listed on the Official List of the UK Listing Authority in December 2004. The Company's has operations in the UK, R&D and production facilities in Tampere, Finland, and a US office in Oklahoma City, OK. This announcement includes 'forward-looking statements' which include all statements other than statements of historical facts, including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group's products), and any statements preceded by, followed by or that include forward-looking terminology such as the words 'targets', 'believes', 'estimates', 'expects', 'aims', 'intends', 'will', 'can', 'may', 'anticipates', 'would', 'should', 'could' or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to Inion's funding requirements, regulatory approvals, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statement. |
Posted at 24/11/2006 08:05 by pugugly 2/10/06 management said:- it knows of no reason for the recent fallin the company's share price. It confirmed that it remains confident of meeting the current market expectations. Today it says:- Inion believes that its 2006 sales targets will not be met. The Board anticipates that revenues for 2006 will be approximately 5.7 million and therefore below current market expectations. Once again management have shown their Incompetence. If Revenues are only going to be 5.7 million how big will be the loss and cash burn? Rate of sales has DECLINED since the 1st half. Pretax losses were 6 million in 1st half, R&D up sales down could be looking for a loss of between 7 tyo 9 million (imo&dyor). This needs a rapid t/o or trade sale to give the poor investors back a fraction of their investment - UNLIKELY - Probably a rescue dilutive rights if any idiots will support. Usual cautions apply (imo & dyor). |
Posted at 02/2/2006 14:59 by kevin511 Investors Chronicle had one broker strong sell for last couple of months. That has not yet been updated but it has in last few days been joined by a Strong Buy!!! |
Posted at 14/12/2005 21:01 by ruby2 This was tipped in investors testicles recently---Why is it plummeting? |
Posted at 21/10/2003 11:57 by clem Welcome Ample Users.Hi there and welcome to ADVFN. ADVFN is the leading stocks and shares site in the UK and is packed with features designed to help the private investor maximise their portfolios. We have FREE real time prices, trades, RNS and the biggest liveliest bulletin boards in the UK. Please explore the site at your leisure and take a look at our advanced tools such as Fundamentals, Top Lists and Data Downloads. ADVFN has more than just FREE real time prices direct from the London Stock Exchange: it has Nasdaq, NYSE, Amex, US Indices, French Prices, Forex, LIFFE, Covered Warrants and UK Level 2, not to mention a plethora of other data like OFEX prices, Covered Warrants and sporting odds. The list is exhaustive. ADVFN is a vibrant site, with new features added every month. While other sites have fallen by the wayside ADVFN has gone from strength to strength. ADVFN brings you the most advanced tools and more and more information each month. ADVFN is committed to the future of the private investor and we are glad to have you come on board. |
Posted at 10/8/2001 16:14 by calleva 31.65PRNS Number:3627I AMP (UK) PLC 10 August 2001 10 August 2001 This announcement is not for release, publication or distribution in or into the United States, Canada, Australia, Japan, or the Republic of Ireland RECOMMENDED CASH OFFER by AMP (UK) Investment Services Limited (the "Offeror"), a wholly owned subsidiary of AMP Limited ("AMP") for Interactive Investor International plc ("Interactive Investor") OFFER DECLARED WHOLLY UNCONDITIONAL The board of the Offeror announces that the Offer for Interactive Investor has been declared wholly unconditional. As at 1.00 p.m. on 10 August 2001, valid acceptances of the Offer had been received in respect of a total of 148,116,420 Interactive Investor Shares, representing approximately 83.84 per cent in nominal value of the Interactive Investor Shares to which the Offer relates and approximately 88.85 per cent in nominal value of the current existing issued share capital of Interactive Investor. As at close of business on 9 August 2001, the Cash Reserves of Interactive Investor were approximately #49.26 million. In accordance with the basis of calculation of the Additional Consideration set out in the Offer Document, the maximum Additional Consideration of 1.65 pence per share will be payable. Accepting shareholders will therefore receive a total of 31.65 pence in cash for each Interactive Investor Share. On this basis, the Offer values the existing issued and to be issued share capital of Interactive Investor, assuming the exercise of all options to acquire Interactive Investor Shares with exercise prices at or below 31.65 pence, at approximately #55 million. The Offer, which is now declared wholly unconditional, will remain open for acceptances until further notice in respect of all Interactive Investor Shares currently in issue and any further Interactive Investor Shares unconditionally allotted or issued, (whether as a result of the exercise of options under the Interactive Investor Share Option Scheme, or otherwise) on or before 5.00 p.m. on 31 August 2001. However, the Offer is not being extended to any Interactive Investor Shares which have not been unconditionally allotted or issued by 5.00 p.m. on 31 August 2001. Interactive Investor Shareholders who have not yet accepted the Offer and wish to do so should complete and return their Forms of Acceptance as soon as possible. If any Interactive Investor Shareholders require another Form of Acceptance they should contact Computershare Investor Services PLC on 0870 8893106. The consideration payable to Interactive Investor Shareholders will be dispatched within 14 days of today's date in respect of acceptances received by that date which are valid and complete in all respects, and within 14 days of the date of receipt in respect of any further acceptances which are received after today's date and which are valid and complete in all respects. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
